Tidningen il Giornali, Italien skriver att italienska forskare har hittat en medicin som blockerar virusets reproduktion. Det är ett blodförtunnande läkemedel som använts i bla Japan under lång tid.
Och visat sig ha en blockerande förmåga på Covid-19.
Universitetssjukhuset i Padua, Italien har tagit fram studien. Läkemedlet har inget svenskt namn, men heter här
nafamostat mesylate
https://en.wikipedia.org/wiki/Nafamostat
Artikeln är knappt 4 timmar gammal, maskinöversatt från italienska till engelska här, det visar så goda resultat att intensivvård kanske inte behövs:
https://www.ilgiornale.it/news/cronache/farmaco-pu-bloccare-covid-19-ha-duplice-utilit-1944258.html
Citat:
The drug that blocks Covid: "Thus empties intensive care"
May 6, 2021 - 20:37
The University of Padua is studying a potential anti-Covid drug that would be able to block an enzyme that favors the replication of the virus and thrombosis. "Blocks both mechanisms and avoids the serious effects of the disease"
Citat:
While proceeding with the vaccinations, research and science are working "under the radar " to develop an anti-Covid drug that can prevent the development of the serious disease: from this point of view, excellent news could soon arrive from Italy.
The Italian study
The study, approved by the Technical Scientific Committee (Cts) of the Istituto Superiore di Sanità, by the National Ethics Committee of the Spallanzani Hospital in Rome and by Aifa , will be conducted in collaboration with the Covid-19 Units of the University Hospital of Padua. The controlled clinical study is designed and coordinated by prof. Gian Paolo Rossi , Director of the Emergency Medicine Operating Unit and of the School of Specialization in Emergency and Urgency Medicine, and by Prof. Teresa Seccia and will use nafamostat mesylate , a drug used for years in Japan as a generic anticoagulant drug which has shown an excellent safety profile in all studies conducted so far. "If the expectations are confirmed, the drug will be able to keep many Covid-19 patients out of intensive care and save many lives - says Prof. Seccia to Insalutenews - and could also be effective against the different variants of Covid-19, but we will define it better in the course of our study ".
Här beskrivs verkningssättet på läkemedlet, det blockerar ett viktigt enzym som viruset behöver för att fungera och reproducera sig:
Citat:
How the drug works
But what is this nafamostat mesylate? “We are facing another case of drug that could potentially be useful: in fact, it is a small molecule known for its anticoagulant and antithrombotic activity . Starting from this assumption, the usual molecular modeling studies that have been carried out intensively in recent months during the height of the pandemic, have shown that this anticoagulant action occurs through the inhibition of some enzymes of the serine kinase family (family of enzymes, ed. ) and one of these in particular, TMPRSS2, not only has a pro-thrombotic effect but also has an effect in favor of the replication of the virus, it presents these two characteristics together ", he explained exclusively to our journal.Renato Bernardini , Full Professor of Pharmacology at the University of Catania and member of the Superior Health Council, who explained to us how nafamostat powerfully inhibits this enzyme avoiding both thrombosis and viral replication, due to the well-known Spike protein.
Ett viktigt enzym i kroppen TMPRSS2, utgör inkörsporten för viruset, och läkemedlet blockerar detta enzym:
Citat:
The danger of the enzyme
In practice, the TMPRSS2 enzyme is dangerous for health because "it favors the penetration of the virus into the cell and amplifies its ability to reproduce", adds Prof. Bernardini. The advantage , in addition to discovering the benefits that can be obtained against Sars-Cov-2 disease, is that the drug is already in use on the market, which is why the safety is well known, the parameters are already well known and well associates the two mechanisms by inhibiting viral replication on the one hand, and by antagonizing the serious effects of the viral disease, which are the thrombotic effects that occur in more advanced stages of the disease, on the other ".
256 patienter med konstaterad Covid-19 har nyligen behandlats med mycket gott resultat, i gynnsamma fall kan medicinen förkorta sjukhusvistelse, eller rent av förhindra den helt, förutsatt att patienten har ett någorlunda fungerande immunsystem:
Citat:
When and how it should be used
But in which cases could nafamostat mesylate be used? "If we divide the phase of the disease into mild or with few symptoms, an intermediate phase where lung involvement occurs with cough and pneumonia and severe phase where the disease has pulmonary thromboembolic outcomes (and not only) - the pharmacologist tells us - its evolution to the intermediate stage(or moderate) is the moment in which nafamostat could be used to try to avoid a situation of thrombosis and severe embolism of the lungs and other organs. "The clinical studies, which will be conducted on 256 patients with Sars-Cov-2 and hospitalized but not so serious as to be hospitalized in intensive care, will still have to confirm the antiviral potential of the drug which would be an important milestone because "the decreased viral replication could be correlated to a decreased severity of the clinical picture". Administration would take place intravenously. : "if we consider, then, that it is indicated in the moderate / severe phases of the disease, it should be administered exclusively in the hospital", says Prof. Bernardini.
På 48 platser runt om i världen pågår samma undersökning med testning av samma läkemedel, vilka också har visat på lovande resultat:
Citat:
As mentioned at the beginning, the study was approved by the ISS and by Spallanzani because this drug is already used in the clinic as an anticoagulant. "The antiviral aspect, on the other hand, it was not known and must be studied in the clinic: for this reason, authorization was requested from AIFA which approved the study design, sent it to the Spallanzani ethics committee which in turn approved it and the drug is today studied at the University of Padua in the Unit of Prof. Gian Paolo Rossi ". Attention, however, because the Italian study is part of one of the 48 clinical trials currently underway worldwide for nafamostat mesylate in Covid," the Italian one he is one of the 48 ”, adds the pharmacologist. It can be easily deduced that, given the high number of trials exclusively for this drug, the potential for success in the treatment of Covid could grow enormously (fortunately).
Man ser dock de största möjligheterna med de nya monoklonala antikropparna, där man förväntar nya spännande resultat nästa vecka:
Citat:
At what point is the research
But what are the news, if any, for other potential anti-Covid drugs? “I am sure that we will continue, for a long time, to hear about new therapeutic potentials but, at present, I do not feel like saying that the solution drug has been discovered. We are certainly a good point, we have learned a lot from the disease but also from the failures and therapeutic successes - Bernardini tells us - Now we have an increased ability to place drugs compared to the beginning of the pandemic, when very little was known and went for attempts ". It is very fresh news that an experimental antibody-based drug could neutralize and fight the Covid variants according to what emerged from the studies of the US pharmaceutical company Eli Lilly ( the same of monoclonal antibodies) and Canada's AbCellera Biologics, who will reveal the results of the trial next week. According to the first advances, the antibodies would act by attacking the virus and its mutations, which means that the drug could maintain its effectiveness over time and against Covid variants. British Prime Minister Boris Johnson has suggested that antiviral treatments could be provided to people for home care, and could be seen as an " additional medical line of defense " against Coronavirus.
Ordlista:
thrombosis = omfattande blodproppar
anticoagulant drug = blodförtunnande läkemedel
inhibition = blockering
Upptäckten i Italien av detta nya användningsområde av ett redan etablerat läkemedel verkar lovande att det lär kunna blockera andra virus, även de nyare varianterna (mutationerna) av Covid-19.
